NATCO launches first universal Version of Nexavar drugs inside the US marketplace by admin- Wednesday, June 1st, 2022 03:30:18 PM
NATCO Pharma introduced the release of the primary customary version of Nexavar (Sorafenib) Tablets in two hundred mg energy inside the US market. The product can be launched via NATCO’s commercial accomplice Viatris, a international pharmaceutical corporation.
Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), superior Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). For more records talk over with the overall prescribing information or other scientific assets.
Nexavar registered sales of USD 69.7 million for the year ending December 2021 as in keeping with industry income statistics.